What is the place of aspirin in venous thrombosis prophylaxis?;Quelle place pour l'aspirine en prophylaxie antithrombotique veineuse?

Annales de Cardiologie et d'Angeiologie

Volumn 51, Issue 5, 2002, Pages 296-302

  Elalamy, I ^a,b   Hatmi, M ^b  

^a HÔTEL DIEU   (France)

^b INSTITUT PASTEUR   (France)

Author keywords

Antithrombotic prophylaxis; Aspirin; Pulmonary embolism; Venous thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; THROMBOXANE A2;

CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG EFFECT; HUMAN; LUNG EMBOLISM; META ANALYSIS; MORTALITY; PROPHYLAXIS; PROTEIN SYNTHESIS INHIBITION; REVIEW; TREATMENT OUTCOME; VEIN THROMBOSIS;

EID: 0036868338     PISSN: 00033928     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-3928(02)00131-2     Document Type: Short Survey

References (37)

1. Virchow R. Newer fall von todlichen emboli der lungenarterere. Arch Pathol Anat 1856;15:925-9.
2. Patrono C, Coller B, Dalen JE, Fuster V, Gent M, Harker LA, Hirsh J, Roth G. Platelet-active drugs the relationships among dose, effectiveness and side effects. Chest 1998;114:470S-88S.
3. Lévesque H, Lafont O. L'aspirine à travers les siècles: Rappel historique. Rev Med Interne 2000;21(suppl 1):8s-17s.
4. Beaumont JL, Caen J, Bernard J. Influence de l'acide acetylsalicylique dans les maladies hémorragiques. Sang 1956;27(243).
5. Quick AJ. Salicylates and bleeding: The aspirin tolerance test. Am J Med Sci 1967;252:265-9.
6. Gibson PC. Aspirin in the treatment of vascular diseases. Lancet 1948;ii:1172-4.
7. O'Brien JR. Effects of salicylates on human platelets. Lancet 1968;1:779-83.
8. Vane JR. Inhibition of prostaglandin biosynthesis as a mechanism of action of aspirin like drugs. Nature New Biol 1971;231:232-5.
9. Xie W, Chipman JG, Robertson DL. Expression of a mitogenresponsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci 1991;88:2692-6.
10. Weber AA, Zimmermann KC, Meyer-Kirchrath J, Schror K. Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance. Lancet 1999;353:900.
11. Cryer B, Feldman M. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med 1998;104:413-21.
12. Schrör K. Aspirin and platelets: The antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis. Semin Thromb Hemost 1997;23:349-56.
13. Leo R, Ghiselli A, Juliano L, Violi F. Detection of hydroxyl radicals by the salicylate bishydroxylation during arachidonic acid dependent platelet activation. Thromb Haemost 1995;73(991).
14. Atkinson DC, Collier HO. Salicylates: Molecular mechanism of therapeutic action. Adv. Pharmacol. Chemother 1980;17:233-40.
15. Snyder B, Khurana U, Aljada A, Love J, Izzo JL, Dandonna P. Effects of aspirin on oxygen free radical generation by leucocytes in whole blood. Circulation 1993;88(3020A).
16. Quyyumi AA. Effects of aspirin on endothelial dysfunction in atherosclerosis. Am J Cardiol 1998;82(Suppl 10):31-3.
17. Lopez-Farré A, Caramelo C, Esteban A, Alberola ML, Millas I, Monton M, Casado S. Effects of aspirin on platelet-neutrophil interactions: Role of nitric oxide and endothelin-1. Circulation 1995;91:2080-8.
18. Osnes LTN, Westvik AB, Joo GB, Okkenhaug C, Kierluf P. Sodium salicylate inhibits lipolysaccharide induced tissue factor (TF) and tumor necrosis factor (TNFalpha)-synthesis in vitro. Thromb Haemost 1995;73(1082).
19. Quick AJ, Cleasceri L. Influence of acetylsalicylic acid and salicylamide on the coagulation of blood. J Pharmacol Exp Ther 1960;128:95-9.
20. Loew D, Vinazzer H. Dose-dependent influence of acetylsalicylic acid on platelet functions and plasmatic coagulation facors. Haemostasis 1976;5:239-49.
21. Szczeklik A, Krzanowski M, Gora P, Radwan J. Antiplatelet drugs and generation of thrombin in clotting. Blood 1992;80:2006-11.
22. Kessels H, Beguin S, Andree H. Measurement of thrombin generation in whole blood: The effect of heparin and aspirin. Thromb Haemost 1994;72:78-83.
23. Undas Undas A, Undas R, Musial J, Szczeklik A. A low dose of aspirin (75 mg/day) lowers thrombin generation to a similar extent as a high dose of aspirin (300 mg/day). Blood Coagul Fibrinolysis 2000, Apr; 11(3):231-4.
24. Szczeklik A, Musial J, Undas A, Gajewski P, Gora P, Swadzba J, Jankowski M. Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemia. J Am Coll Cardiol 1999;33:1286-93.
25. Fatah K, Beving H, Albage A, Ivert T, Blomback M. Acetylsalicylic acid may protect the patient by increasing fibrin gel porosity: Danger of withdrawing treatment. Thromb Haemost 1995;73(1228).
26. Bjornsson TD, Scneider DE, Berger H. Aspirin acetylates fibrinogen and enhances fibrinolysis: Fibrinolytic effect is independent of changes in plasminogen activator levels. J Pharmacol Exp Ther 1988;250:154-60.
27. Williams S, Fatah K, Hjemdahl P, Blomback M. Better increase in fibrin gel porosity by low dose than intermediate dose acetylsalicylic acid. Eur Heart J 1998;9(11):1666-72.
28. Alhaddad IA, Tkaczevski L, Siddiqui F, Mir R, Brown EJ. Aspirin henances the benefits of late reperfusion on infarct shape: A possible mechanism of the beneficial effects of aspirin on survival after acute myocardial infarction. Circulation 1995;91:2819-23.
29. Weber C, Erl W, Pietsch A, Weber PC. Aspirin inhibits Nuclear-Factor Kappa B mobilization and monocyte adhesion in stimulated human endothelial cells. Circulation 1995;91:1914-7.
30. Cronstein BN, Montesinos MC, Weissmann G. Salicylates and sulfasalazine but not glucocorticoids inhibit leukocyte accumulation by an adenosine-dependent mechanism that is independent of inhibition of prostaglandin synthesis and P105 of NFKB. Proc Natl Acad Sci 1999;96:6377-81.
31. Santos MT, Valles J, Aznar J, Marcus AJ, Broekman MJ, Safier LB. Prothrombotic effects of erythrocytes on platelet reactivity. Reduction by aspirin. Circulation 1997;95:63-8.
32. Mabro M, de Gramont A. L'aspirine contre le cancer. Rev Med Interne 2000;21(suppl 1):60s-7s.
33. McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: A review of 17 epidemiologic studies. Neurology 1996;47:425-32.
34. Collaborative overview of randomised trials of antiplatelet therapy. I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ 1994, Jan 8;308(6921):81-106.
35. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet 2000, Apr 15;355(9212):1295-302.
36. Thomas DP, Parker M, Kalsi GS, Smulders Y, Tauzeeh SM, Mahe I, Bergmann JF, Mahe E, Caulin C, Cimminiello C, Cohen A, Quinlan D. PEP trial. Pulmonary Embolism Prevention Lancet 2000, Jul 15;356(9225):247 discussion 250-251.
37. Hirsh J, Dalen J, Guyatt G. The sixth ACCP guidelines for antithrombotic therapy for prevention and treatment of thrombosis. American College of Chest Physicians. Chest 2001, Jan;119(1 Suppl):1 S-2S.